Status:
WITHDRAWN
Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis
Lead Sponsor:
Larkin Community Hospital
Conditions:
Allergic Rhinitis
Nasal Congestion
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Allergic rhinitis is defined as the symptoms of sneezing, nasal itching, airflow obstruction, and, mostly, clear nasal discharge caused by IgE-mediated reactions against inhaled allergens and involvin...
Detailed Description
Allergic rhinitis is defined as the symptoms of sneezing, nasal itching, airflow obstruction and, mostly, clear nasal discharge caused by IgE-mediated reactions against inhaled allergens and involving...
Eligibility Criteria
Inclusion
- No oral steroids
- No oral antihistamine
- No Nafasoline If the patient needs rescue treatment, he will go to the intervention arm with chlorpheniramine or with the combination of chlorpheniramine and fluticasone. If a participant experienced a severe acute nasal block, the investigator could authorize the use of a short course of oxymetazoline spray for a maximum of 3 days and a maximum total of 1 day during the treatment period. Oxymetazoline should not be used within 24 hours of a scheduled visit during the study.
Exclusion
- Large (grade 3) polyps, indicating severe nasal obstruction
- Surgical treatment for nasal polyps during the last 3 months
- Cystic fibrosis
- Purulent nasal infection
- Allergic rhinitis
- Any disease likely to interfere with the study parameters or which gave evidence of any serious or unstable concurrent disease or psychological disorder
Key Trial Info
Start Date :
July 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04790487
Start Date
July 30 2019
End Date
December 30 2021
Last Update
October 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Larkin Health System
South Miami, Florida, United States, 33143